[go: up one dir, main page]

PL2099769T3 - Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych - Google Patents

Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych

Info

Publication number
PL2099769T3
PL2099769T3 PL07862644T PL07862644T PL2099769T3 PL 2099769 T3 PL2099769 T3 PL 2099769T3 PL 07862644 T PL07862644 T PL 07862644T PL 07862644 T PL07862644 T PL 07862644T PL 2099769 T3 PL2099769 T3 PL 2099769T3
Authority
PL
Poland
Prior art keywords
dihydropyrimidin
yls
oxo
treatment
proliferative diseases
Prior art date
Application number
PL07862644T
Other languages
English (en)
Inventor
Zhuoliang Chen
Run-Ming David Wang
Ming Chen
Christopher Sean Straub
Leigh Zawel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2099769T3 publication Critical patent/PL2099769T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL07862644T 2006-12-07 2007-12-07 Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych PL2099769T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87343606P 2006-12-07 2006-12-07
EP07862644A EP2099769B1 (en) 2006-12-07 2007-12-07 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
PCT/US2007/025096 WO2008073305A1 (en) 2006-12-07 2007-12-07 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
PL2099769T3 true PL2099769T3 (pl) 2011-12-30

Family

ID=39267989

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07862644T PL2099769T3 (pl) 2006-12-07 2007-12-07 Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych

Country Status (15)

Country Link
US (2) US8048886B2 (pl)
EP (1) EP2099769B1 (pl)
JP (1) JP2010512321A (pl)
KR (1) KR20090086244A (pl)
CN (1) CN101535273B (pl)
AT (1) ATE517873T1 (pl)
AU (1) AU2007332861A1 (pl)
BR (1) BRPI0720050A2 (pl)
CA (1) CA2670726A1 (pl)
ES (1) ES2370536T3 (pl)
MX (1) MX2009005938A (pl)
PL (1) PL2099769T3 (pl)
PT (1) PT2099769E (pl)
RU (1) RU2009125617A (pl)
WO (1) WO2008073305A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218862D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
MY186311A (en) 2013-12-20 2021-07-08 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
KR102697816B1 (ko) 2015-08-05 2024-08-21 브리스톨-마이어스 스큅 컴퍼니 신규 치환된 글리신 유도된 fxia 억제제
RU2670204C1 (ru) * 2017-12-01 2018-10-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-тиоурацила, обладающие противоаденовирусной активностью
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20230005949A (ko) * 2020-05-01 2023-01-10 콘스텔레이션 파마슈티칼스, 인크. Trex1의 조절제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
KR20080022092A (ko) * 2005-06-08 2008-03-10 노파르티스 아게 유기 화합물
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds

Also Published As

Publication number Publication date
CN101535273B (zh) 2012-04-11
KR20090086244A (ko) 2009-08-11
US20110319614A1 (en) 2011-12-29
BRPI0720050A2 (pt) 2014-10-14
CA2670726A1 (en) 2008-06-19
EP2099769A1 (en) 2009-09-16
RU2009125617A (ru) 2011-01-20
US20100249405A1 (en) 2010-09-30
MX2009005938A (es) 2009-06-17
CN101535273A (zh) 2009-09-16
JP2010512321A (ja) 2010-04-22
WO2008073305A1 (en) 2008-06-19
EP2099769B1 (en) 2011-07-27
US8048886B2 (en) 2011-11-01
AU2007332861A1 (en) 2008-06-19
PT2099769E (pt) 2012-08-31
ES2370536T3 (es) 2011-12-19
ATE517873T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
PL2099769T3 (pl) Związki 6-okso-1,6-dihydropirymidyn-2-ylowe do leczenia chorób proliferacyjnych
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
WO2011080568A8 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2009006706A (es) Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
CA2871471C (en) Dna-pk inhibitors
IN2012DN00971A (pl)
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY150542A (en) Cmet inhibitors
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
IN2012DN03883A (pl)
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
MY150460A (en) Smac peptidomimetics useful as iap inhibitors
WO2010115491A3 (en) Piperidine and piperazine derivatives as autotaxin inhibitors
GEP20146072B (en) New compounds
MY160468A (en) Novel amino azaheterocyclic carboxamides
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов